Precision Medicines Market Size, Production, Sales, Average Product Price, Market Share, Import vs Export 

Emerging Paradigm Shifts in the Precision Medicines Market 

The Precision Medicines Market is experiencing a profound transformation driven by a rapidly evolving healthcare ecosystem, where personalized interventions are becoming the rule rather than the exception. According to Datavagyanik, a robust expansion in molecular diagnostics, next-generation sequencing, and companion diagnostics is strengthening the backbone of precision-based therapeutics. For instance, the growing burden of cancer globally, with nearly 19.3 million new cases in 2020, has fueled an unprecedented surge in targeted therapies. Oncology alone accounted for approximately 35% of the Precision Medicines Market Size, with immuno-oncology therapies leading the way. The rising adoption of biomarkers to stratify patients precisely for optimal treatment regimens continues to unlock new revenue streams in the Precision Medicines Market. 

Precision Medicines Market Driven by Genomics Revolution 

The Precision Medicines Market is directly benefiting from the dramatic reduction in genomic sequencing costs, which have fallen from $100 million per genome in 2001 to less than $500 today. This cost deflation has democratized access to genomic insights, empowering physicians to make personalized treatment decisions based on actionable mutations and pathways. For instance, the market has seen significant growth in pharmacogenomics-guided dosing strategies for cardiovascular drugs and psychiatric medications, reducing adverse effects and improving efficacy profiles. According to Datavagyanik, the surge in genomics-based research pipelines will continue to stimulate the Precision Medicines Market as large-scale biobanks and cohort studies accelerate drug discovery efforts. 

Increasing Demand for Targeted Cancer Therapies in the Precision Medicines Market 

In the Precision Medicines Market, oncology remains the most influential therapeutic domain, owing to increasing investments in molecularly targeted drugs. For example, targeted therapies represented over 40% of all cancer treatments in 2022, and the segment is projected to grow by 12% CAGR through 2030. Therapies such as tyrosine kinase inhibitors, immune checkpoint inhibitors, and monoclonal antibodies are witnessing high adoption, reflecting a robust expansion of their indication bases across solid tumors and hematologic malignancies. According to Datavagyanik, these targeted approaches are poised to reshape treatment protocols for lung, breast, and colorectal cancers, which collectively affect more than 7 million patients annually worldwide. These factors will reinforce sustained growth in the Precision Medicines Market. 

Precision Medicines Market Gains Momentum with Companion Diagnostics 

The integration of companion diagnostics is a powerful enabler within the Precision Medicines Market, enhancing treatment precision while reducing trial-and-error approaches. The segment for companion diagnostics surpassed $6 billion in 2023, and is forecast to cross $12 billion by 2030, registering a CAGR exceeding 10%. For instance, HER2 testing for breast cancer, EGFR mutation analysis for non-small cell lung cancer, and KRAS testing in colorectal cancers are now standard clinical practices. According to Datavagyanik, the symbiotic relationship between therapeutic developers and diagnostic innovators will accelerate regulatory approvals and shorten market entry timelines for novel precision therapeutics, further boosting the Precision Medicines Market. 

Expanding Precision Medicines Market Fueled by Rare Disease Therapies 

Rare and orphan diseases are creating a fertile ground for the Precision Medicines Market as traditional treatment models have largely failed to address the needs of small, genetically distinct patient populations. For example, over 7,000 rare diseases impact 400 million people globally, with only 5% having approved therapies. Gene therapies and antisense oligonucleotides are emerging as game-changers, exemplified by their application in conditions like spinal muscular atrophy and Duchenne muscular dystrophy. According to Datavagyanik, this underserved therapeutic landscape provides a multi-billion-dollar opportunity for the Precision Medicines Market to design innovative, mutation-specific interventions with transformative impact. 

Precision Medicines Market Leveraging Artificial Intelligence and Big Data 

Artificial intelligence and big data are transforming the Precision Medicines Market by enabling complex analysis of multi-omic datasets, imaging data, and electronic health records. For instance, AI-driven pattern recognition can identify subtle genomic variations and link them to treatment response with unprecedented speed and accuracy. In 2024, AI-enabled clinical decision support systems are projected to reach $2.5 billion in global sales, directly reinforcing growth in the Precision Medicines Market. According to Datavagyanik, such digital platforms will drive more precise stratification of patients in oncology, neurology, and infectious diseases, unlocking further commercial potential. 

Growing Acceptance of Cell and Gene Therapies Boosts Precision Medicines Market 

The Precision Medicines Market is witnessing heightened adoption of cell and gene therapies, underpinned by regulatory approvals and commercial launches of landmark products. For instance, the approval of CAR T-cell therapies for relapsed and refractory hematologic cancers has catalyzed a new era of living drugs, with the market for CAR T therapies alone expected to grow at 24% CAGR through 2030. In addition, gene therapies for inherited retinal dystrophies and hemophilia are demonstrating durable clinical benefits, reducing lifetime treatment costs by 30% to 50% compared to chronic standard-of-care. According to Datavagyanik, these therapies will form a cornerstone of the Precision Medicines Market, driving profound clinical and economic impact. 

Precision Medicines Market Propelled by Personalized Infectious Disease Management 

Infectious diseases represent another critical growth lever in the Precision Medicines Market. The COVID-19 pandemic, for example, showcased how precision-based approaches using mRNA vaccines could be designed, tested, and distributed in record time. Beyond COVID-19, precision antimicrobials and pathogen-specific therapies are gaining traction to combat multidrug-resistant infections, which are projected to cause 10 million deaths annually by 2050. According to Datavagyanik, personalized infectious disease management will account for an expanding share of the Precision Medicines Market, with applications extending to HIV, hepatitis, and tropical diseases. 

Precision Medicines Market Size Benefits from Regulatory Support and Reimbursement Pathways 

The Precision Medicines Market Size is also positively influenced by favorable regulatory frameworks and evolving reimbursement models. For instance, the U.S. FDA has established accelerated pathways, including breakthrough therapy designations and priority reviews, to expedite precision-based drug approvals. Europe and Asia-Pacific are following suit with adaptive licensing and precision therapy pilot programs. In addition, payers are increasingly supportive of outcomes-based reimbursement contracts for precision therapies, incentivizing manufacturers to deliver higher-value treatments. According to Datavagyanik, these frameworks will continue to expand market access and drive further adoption of innovations across the Precision Medicines Market. 

Precision Medicines Market Thrives on Collaborations and Strategic Alliances 

Collaborative business models are cementing their importance in the Precision Medicines Market, as pharmaceutical companies partner with biotechnology startups, academic research centers, and diagnostic developers. For example, the number of strategic alliances in the oncology precision segment grew by 20% in 2023 alone, with high-profile deals exceeding $4 billion in disclosed transaction values. According to Datavagyanik, these partnerships are essential to accelerate clinical trials, share risk, and integrate disruptive technologies such as CRISPR gene editing. As a result, the Precision Medicines Market is poised to maintain a dynamic innovation pipeline well into the next decade. 

Increasing Patient Awareness and Advocacy Reshaping the Precision Medicines Market 

The Precision Medicines Market is also seeing a cultural shift as patients become more empowered and informed about their treatment choices. Advocacy groups are playing a vital role in promoting genetic testing and demanding greater transparency from drug developers. For example, patient-led initiatives in breast and ovarian cancers have increased genetic testing uptake by over 30% in key markets over the past five years. According to Datavagyanik, this rise in patient-driven demand will strengthen the Precision Medicines Market by encouraging healthcare systems to adopt more tailored therapeutic pathways aligned with individual patient profiles. 

Future Outlook for the Precision Medicines Market 

Looking ahead, the Precision Medicines Market is expected to experience compound annual growth rates exceeding 10% over the next five years, supported by technological breakthroughs, patient-centric delivery models, and global expansion into emerging markets. For instance, precision oncology is forecast to account for more than 40% of all cancer drug spending by 2030, illustrating the deep penetration of targeted interventions. According to Datavagyanik, the Precision Medicines Market will continue to disrupt traditional “one-size-fits-all” approaches, creating a more resilient, equitable, and sustainable healthcare ecosystem. 

 

“Track Country-wise Precision Medicines Production and Demand through our Database”

• • • Precision Medicines sales volume database for 27+ countries worldwide

 

Geographical Expansion Driving the Precision Medicines Market 

The Precision Medicines Market is undergoing rapid geographical diversification, reflecting both matured and emerging economies’ willingness to invest in personalized therapies. North America continues to dominate, accounting for nearly 45% of the global market in 2024, supported by robust regulatory frameworks and an advanced reimbursement environment. For instance, the United States has seen an 18% year-on-year growth in genomic testing adoption, fueling demand for companion diagnostics and targeted oncology drugs. Meanwhile, Europe represents the second-largest regional segment in the Precision Medicines Market, driven by strong uptake of precision therapeutics in Germany, France, and the United Kingdom. According to Datavagyanik, Asia-Pacific is the fastest-growing region, projected to expand at over 14% CAGR through 2030, supported by growing investments in next-generation sequencing and local biopharmaceutical capabilities. Countries such as China and India are advancing large-scale precision oncology programs, opening up fresh opportunities in the Precision Medicines Market. 

Rising Local Investment and Precision Medicines Manufacturing Capacity 

Precision-based therapies are transforming not only the treatment paradigm but also the global Precision Medicines Manufacturing landscape. For example, North American players are investing heavily in advanced cell therapy manufacturing suites, while Europe is ramping up biologics production with modular GMP facilities. According to Datavagyanik, Asia-Pacific has emerged as a strategic hub for Precision Medicines Manufacturing, with China investing more than $5 billion in biomanufacturing parks between 2022 and 2024. Facilities are increasingly deploying single-use bioreactors and closed manufacturing systems to boost flexibility and reduce contamination risks, supporting highly personalized production runs. Such as in Japan, where regenerative medicine frameworks have enabled faster commercialization of autologous therapies, precision drug manufacturers are localizing their production to meet strict quality and traceability requirements. These shifts will redefine the competitive map of the Precision Medicines Market. 

Segmentation Dynamics in the Precision Medicines Market 

The Precision Medicines Market can be segmented along therapeutic area, technology, and end-user profiles, each showing dynamic growth. Oncology remains the dominant segment, capturing more than 40% of total revenues in 2024, reflecting expanding biomarker-driven approvals. For example, breast cancer precision therapeutics have grown 15% annually, owing to expanded HER2, BRCA, and PIK3CA testing protocols. Beyond oncology, rare diseases form a high-potential segment within the Precision Medicines Market, with gene therapies forecast to grow at over 20% CAGR through 2030 as hundreds of monogenic disorders move into clinical trial pipelines. Infectious diseases, such as HIV and hepatitis C, are also seeing growing demand for personalized treatment regimens, supported by advances in molecular diagnostics and companion assays. According to Datavagyanik, neurology and immunology will emerge as the next innovation frontiers within the Precision Medicines Market, driven by better understanding of genetic underpinnings in conditions such as Alzheimer’s disease and multiple sclerosis. 

Technological Segmentation Powering Precision Medicines Market Growth 

In technology-based segmentation, molecular diagnostics dominate the Precision Medicines Market with a share exceeding 50% of supporting technologies in 2024, followed by next-generation sequencing and digital pathology solutions. For example, the uptake of liquid biopsy tests has expanded by 22% over the past two years, reflecting demand for minimally invasive solutions to monitor cancer mutations in real time. Artificial intelligence algorithms and digital twin simulations are also emerging to optimize patient selection in complex oncology trials. According to Datavagyanik, these digital health tools will become indispensable pillars of the Precision Medicines Market, allowing faster turnaround for personalized treatment recommendations. As a result, innovation pipelines will become more predictable, cost-effective, and aligned with the principles of precision healthcare. 

Regional Manufacturing Trends Supporting the Precision Medicines Market 

The transformation of Precision Medicines Manufacturing processes is directly shaping the ability to meet patient-specific requirements. For instance, personalized cell therapies require small-batch, patient-tailored production, with stringent chain-of-identity protocols to ensure traceability. In Europe, more than 80% of new precision biomanufacturing facilities are investing in digital monitoring systems to maintain these quality standards. Similarly, Asian contract development and manufacturing organizations are scaling up to offer integrated services — from viral vector manufacturing to final fill-finish for gene therapies. According to Datavagyanik, these developments will improve capacity utilization, reduce time-to-market, and sustain momentum in the Precision Medicines Market by addressing the growing volume of complex, highly customized therapies. 

Pricing Dynamics and the Precision Medicines Market 

Price trends in the Precision Medicines Market reflect a delicate balance between innovation costs and market access. For example, the average price of a precision oncology drug currently exceeds $120,000 per treatment course, yet outcomes-based agreements are emerging to share risks between payers and manufacturers. Cell and gene therapies, some priced over $2 million per administration, are driving discussions around installment-based reimbursement models to expand accessibility. According to Datavagyanik, prices are expected to moderate over the long term as competition rises and biosimilars enter the Precision Medicines Market, especially in monoclonal antibody and targeted therapy classes. At the same time, economies of scale in Precision Medicines Manufacturing and standardized regulatory pathways are likely to bring down costs of production by 15% to 25% within the next five years. 

End-User Dynamics in the Precision Medicines Market 

Hospitals and cancer centers continue to be the largest end-user segment in the Precision Medicines Market, given their ability to support complex molecular testing and integrate multidisciplinary care. For example, over 70% of precision oncology drugs are administered in hospital-based settings, where companion diagnostic capabilities are readily available. Specialty clinics and standalone precision therapy centers are growing rapidly, with Datavagyanik projecting a 14% annual growth in these facilities through 2030, particularly in urban areas with high patient demand. Home-based precision medicine models, supported by digital health platforms and telemonitoring tools, are also gaining acceptance, especially in chronic disease management. These evolving care pathways will reinforce the growth trajectory of the Precision Medicines Market. 

Regional Policy Frameworks Impacting Precision Medicines Market 

The policy landscape is increasingly favorable for the Precision Medicines Market, particularly in high-income countries. For instance, North America’s regulatory ecosystem supports more than 500 active precision drug trials annually, while Europe is advancing conditional approval mechanisms for targeted therapies in rare diseases. Asia-Pacific nations are adopting precision-focused policies, such as China’s National Precision Medicine Plan and India’s genome sequencing missions, to create a strong domestic precision pipeline. According to Datavagyanik, this strategic policy support will accelerate clinical trial recruitment, reduce approval bottlenecks, and incentivize investments in Precision Medicines Manufacturing, fueling sustainable growth of the Precision Medicines Market across regions. 

Supply Chain Optimization Reshaping Precision Medicines Manufacturing 

Optimizing supply chains is essential for Precision Medicines Manufacturing, given the highly customized nature of these therapies. For instance, autologous cell therapies require cold chain logistics under -150°C conditions, with real-time tracking to prevent product loss. European and North American manufacturers are investing in blockchain-enabled traceability solutions to protect product integrity and enhance patient safety. According to Datavagyanik, over 40% of cell and gene therapy manufacturers will adopt blockchain-backed logistics by 2028, reshaping the delivery framework of the Precision Medicines Market. Similarly, contract manufacturers are developing multi-tenant, flexible manufacturing lines that can switch between products rapidly, reducing downtime and enabling faster responses to changing demand patterns. 

Shifts in Global Demand Patterns Across the Precision Medicines Market 

As disease profiles evolve, so does the global demand for the Precision Medicines Market. For example, emerging economies are seeing a surge in cancer cases, with Asia-Pacific expected to contribute nearly 50% of all new cancer diagnoses by 2030. This will require significant scaling of molecular diagnostics and targeted therapies in those regions. Similarly, rare disease diagnosis rates are improving due to better awareness and newborn screening initiatives, expanding the patient base for high-value gene therapies. According to Datavagyanik, this demographic shift will drive regional market expansions, diversify revenue streams, and challenge current manufacturing capacities in the Precision Medicines Market. 

Next-Generation Technologies Reshaping Precision Medicines Market Segmentation 

Rapid adoption of next-generation sequencing, CRISPR-based editing, and multi-omic platforms is expanding the scope of the Precision Medicines Market beyond single-gene targeting. For instance, whole-exome and whole-genome sequencing are increasingly being integrated into routine care in oncology, raising the share of multi-gene panels by 30% in 2024. This expansion allows developers to stratify patients across multiple biomarkers, increasing the efficiency and accuracy of therapeutic targeting. According to Datavagyanik, next-generation platforms will also allow the Precision Medicines Market to evolve toward polygenic disease management, which will become a key growth driver in chronic, complex conditions such as cardiovascular and autoimmune diseases. 

Future Price Outlook in the Precision Medicines Market 

Looking forward, pricing strategies in the Precision Medicines Market will likely shift from traditional per-dose models to performance-based frameworks. For example, European payers are testing multi-year installment payments tied to patient outcomes for gene therapies, while the U.S. is exploring risk-sharing agreements tied to biomarker-defined response rates. Such innovative payment schemes could unlock significant patient access despite high headline prices. Datavagyanik estimates that, with broader acceptance of these models, market penetration of high-cost precision therapies could rise by 20% by 2030. Meanwhile, Precision Medicines Manufacturing will focus on leaner, more automated production systems to support affordable scale-up, helping to moderate overall price trends in the Precision Medicines Market. 

Conclusion of Regional and Segmentation Trends in the Precision Medicines Market 

In conclusion, the Precision Medicines Market is witnessing a multi-faceted transformation across geographies, technologies, and end-user segments, supported by strategic investments in Precision Medicines Manufacturing, policy tailwinds, and technological breakthroughs. For instance, Asia-Pacific’s surge in precision oncology demand, Europe’s policy leadership in rare disease approvals, and North America’s maturity in precision clinical trials are collectively creating a robust and diversified market landscape. According to Datavagyanik, these interwoven dynamics will sustain double-digit growth, expand treatment access, and drive an era of highly personalized, data-driven medicine that redefines the healthcare value chain worldwide. 

“Precision Medicines Manufacturing Database”

• • • Precision Medicines top manufacturers market share for 27+ manufacturers
    • Top 7 manufacturers and top 17 manufacturers of Precision Medicines in North America, Europe, Asia Pacific
    • Precision Medicines sales dashboard, Precision Medicines sales data in excel format

Leading Manufacturers Shaping the Precision Medicines Market 

The precision medicines market is currently defined by a concentrated group of global manufacturers who collectively command roughly 60 to 70 percent of total revenue. These industry leaders have built their positions through sophisticated pipelines, companion diagnostics, strategic alliances, and the ability to combine precision drug development with robust manufacturing capacity. 

Roche stands as a dominant force in the precision medicines market with an estimated 15 percent share. Its powerful combination of diagnostics through Foundation Medicine and targeted oncology therapies including HER2 inhibitors and PARP inhibitors demonstrates an integrated strategy few competitors can match. FoundationOne CDx tests are widely deployed in breast, lung, and colorectal cancers, supporting Roche’s positioning across multiple disease segments. 

Illumina is another vital contributor, with roughly 12 percent share in the precision medicines market. The company has become synonymous with next-generation sequencing, supplying the backbone of genomic data that supports virtually every advanced therapeutic program. Its platforms, including NovaSeq and NextSeq, enable hospitals, academic centers, and pharmaceutical companies to push the boundaries of personalized care. 

AstraZeneca, commanding approximately 10 percent share, has strengthened its leadership through a powerful oncology portfolio. Its antibody-drug conjugate programs, including those developed with Daiichi Sankyo, have transformed treatment outcomes for HER2-positive breast cancer and EGFR-mutated lung cancer. The company’s ability to move rapidly from clinical validation to commercial execution demonstrates how large pharma can remain agile in the precision medicines market. 

Novartis accounts for about 8 percent of global market share, largely due to its advanced targeted oncology products and the development of gene and cell therapies. Novartis’s landmark CAR T-cell product, Kymriah, has reshaped the treatment landscape for pediatric leukemia and lymphoma, showing how personalized cell therapy can drive long-term remissions. Novartis is also investing in radioligand therapies and precision drugs for multiple sclerosis, expanding its reach in hard-to-treat conditions. 

Bristol Myers Squibb maintains approximately 7 percent share of the precision medicines market. The company’s flagship immuno-oncology drugs, Opdivo and Yervoy, continue to anchor its precision-based strategy. By investing in bispecific antibodies and novel checkpoint inhibitors, Bristol Myers Squibb is sustaining growth momentum as first-generation immunotherapies mature. 

Merck holds about 6 percent market share, primarily supported by its market-leading checkpoint inhibitor Keytruda, which has gained approvals across numerous solid tumors. In addition, Merck’s targeted therapies in ovarian and breast cancer, including its partnerships in the PARP inhibitor space, position the company strongly in biomarker-driven segments. 

Pfizer, with roughly 5 percent market share, has recently strengthened its precision medicines portfolio by acquiring Seagen. This move expands Pfizer’s presence in antibody-drug conjugates with products like Adcetris, targeting hematologic cancers. Pfizer’s strategy of linking diagnostics with therapeutic launches reinforces its future role in the precision medicines market. 

Other significant manufacturers include Thermo Fisher Scientific, QIAGEN, Siemens Healthineers, and Abbott, which collectively hold about 10 to 15 percent of the market. These companies focus heavily on molecular diagnostic assays, laboratory automation, and high-throughput testing solutions that underpin precision medicine adoption. Their contribution is critical, enabling patient stratification and personalized treatment pathways in real-world healthcare settings. 

Manufacturer Product Lines and Precision Medicines Market Share 

Each major manufacturer offers flagship products that drive their respective market positions. Roche leverages its FoundationOne CDx testing platform alongside targeted therapeutics such as Herceptin and Kadcyla. Illumina supports precision medicine through NextSeq and NovaSeq sequencers, providing the essential genomic infrastructure. AstraZeneca has introduced advanced antibody-drug conjugates for lung and breast cancer treatment, addressing previously unmanageable patient groups. 

Novartis’s Kymriah has set a new standard for CAR T-cell therapies, while Bristol Myers Squibb continues to build upon the proven track record of Opdivo and Yervoy. Merck relies on Keytruda’s extensive tumor approvals to protect market share, while complementing this portfolio with combination trials and emerging precision pathways. Pfizer and Seagen’s Adcetris, combined with Pfizer’s broader companion diagnostic work, signals a long-term commitment to precision medicines. 

Thermo Fisher and QIAGEN have made vital contributions through multiplex assays, laboratory platforms, and next-generation sequencing reagents. These products are essential to diagnose biomarkers, predict treatment response, and support complex personalized therapy protocols. Smaller but significant mid-sized players in rare disease applications, including BioMarin, Alnylam, and Gilead, are expanding their own targeted pipelines to capture specialized niches within the precision medicines market. 

Competitive Market Share Breakdown 

Overall, large pharmaceutical and diagnostic players account for approximately 60 to 70 percent of the total precision medicines market. Mid-sized biotechnology and specialized rare disease developers capture around 15 to 20 percent. Diagnostic firms and laboratory automation specialists add another 10 to 15 percent through enabling technologies and platforms. This segmentation shows that while the therapeutic side remains highly consolidated, the supporting diagnostic infrastructure continues to diversify as more players invest in scalable, precision-focused solutions. 

Recent Developments and Industry Milestones 

Several important news developments have shaped the precision medicines market over recent months. In June 2025, AstraZeneca and Daiichi Sankyo received US approval for their new antibody-drug conjugate designed for EGFR-mutant non-small cell lung cancer, expanding first-line treatment options and boosting projected sales. 

In March 2025, Bristol Myers Squibb partnered with BioNTech to co-develop a bispecific antibody targeting PD-L1 and VEGF-A, valued at over eleven billion dollars, reflecting a continued appetite for innovation in combination immunotherapies. 

In April 2025, Pfizer finalized the integration of Seagen’s operations to accelerate the commercialization of antibody-drug conjugates globally. This move is expected to expand the reach of Adcetris and other pipeline assets into more solid tumor applications. 

Illumina also announced in early 2025 an expanded suite of whole-genome sequencing panels aimed at rare diseases and oncology, supporting decentralized testing models for regional health systems. This expansion will help smaller laboratories adopt precision solutions without requiring large upfront investments. 

Beyond major approvals, smaller mid-sized companies are actively launching novel RNA therapies, gene-editing programs, and rare disease pipelines to address underserved populations. The combination of advanced regulatory pathways, stronger biomarker discovery tools, and patient advocacy has created fertile ground for a wider group of innovators to compete with established pharmaceutical giants. 

“Precision Medicines Production Data and Precision Medicines Production Trend”

• • • Precision Medicines sales database for historical years, 10 years historical data
    • Precision Medicines sales data and forecast for next 7 years

 

Key Insights that the Precision Medicines Market analysis report presents are:

• Precision Medicines Market revenue and demand by countries
• Break-down of the Precision Medicines Market in terms of application areas, target customers, and other potential market segments
• Areas that are relatively more potential and are faster growing
• Precision Medicines Market competitive scenario, market share analysis
• Precision Medicines Market business opportunity analysis

Global and Country-Wise Precision Medicines Market Statistics

• Global and Country-Wise Precision Medicines Market Size ($Million) and Forecast, till 2030
• Global and Country-Wise Precision Medicines Market Trend Analysis
• Global and Country-Wise Precision Medicines Market Business Opportunity Assessment